You are here

Article info

Article menu
Download PDFPDF
Behcet’s disease
Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity

Authors

  • Ann Cavers Department of Medicine, Division of Rheumatology, NYU Langone Behçet’s Disease Program, NYU Langone Ocular Rheumatology Program, New York University Grossman School of Medicine, New York, NY, USA PubMed articlesGoogle scholar articles
  • Matthias Christian Kugler Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, New York University Grossman School of Medicine, New York, NY, USA PubMed articlesGoogle scholar articles
  • Yesim Ozguler Department of Medicine, Division of Rheumatology, NYU Langone Behçet’s Disease Program, NYU Langone Ocular Rheumatology Program, New York University Grossman School of Medicine, New York, NY, USA Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey Behçet's Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey PubMed articlesGoogle scholar articles
  • Arshed Fahad Al-Obeidi Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA PubMed articlesGoogle scholar articles
  • Gulen Hatemi Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey Behçet's Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey PubMed articlesGoogle scholar articles
  • Beatrix M Ueberheide Department of Biochemistry and Molecular Pharmacology, Department of Neurology, Perlmutter Cancer Center, Proteomics Laboratory at the Division of Advanced Research Technologies, New York University Grossman School of Medicine, New York, NY, USA PubMed articlesGoogle scholar articles
  • Didar Ucar Behçet's Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey Department of Ophthalmology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey PubMed articlesGoogle scholar articles
  • Olivier Manches Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, Université Grenoble-Alpes, Grenoble, France Recherche et Développement, Etablissement Français du Sang Auvergne-Rhône-Alpes, La Tronche, France PubMed articlesGoogle scholar articles
  • Johannes Nowatzky Department of Medicine, Division of Rheumatology, NYU Langone Behçet’s Disease Program, NYU Langone Ocular Rheumatology Program, New York University Grossman School of Medicine, New York, NY, USA Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Johannes Nowatzky, Department of Medicine, Division of Rheumatology, NYU Langone Behçet's Disease Program, NYU Ocular Rheumatology Program, New York University Grossman School of Medicine, New York, NY 10016, USA; Johannes.Nowatzky{at}nyumc.org
View Full Text

Citation

Cavers A, Kugler MC, Ozguler Y, et al
Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity
Annals of the Rheumatic Diseases 2022;81:1603-1611.

Publication history

  • Received January 31, 2022
  • Accepted June 27, 2022
  • First published August 3, 2022.
Online issue publication 
August 01, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.